This review considers trastuzumab's mechanism of action and its clinical value. As shown in Panel A, the four members of the HER family are HER1, HER2, HER3, and HER4. There are receptor-specific ...

Another possible mechanism of action is the preferential exertion of antibody- dependent cellular cytotoxicity on HER2-overexpressing cancer cells. [62] Trastuzumab contains an immunoglobulin G1 ...

Aggressive breast cancer can become unresponsive to monoclonal antibody treatment, but targeting tumor-resident bacteria may extend its effectiveness.

Pertuzumab, an anti-HER2 humanized monoclonal antibody that inhibits receptor dimerization, has a mechanism of action that is complementary to that of trastuzumab, and combination therapy with the ...

The persistence of HER2 overexpression confirms that trastuzumab-mediated ADCC is a feasible mechanism of action for the drug. Trastuzumab plus docetaxel is an approved and well-tolerated ...

13 In ErbB2-positive xenograft models, lapatinib combined with trastuzumab resulted in stabilization of inactive ErbB2 receptor as a result of a mechanism of action attributed to lapatinib, followed ...

In breast cancer, HER2-targeted therapy with trastuzumab has gained significant attention, owing to the dramatic response observed in a subset of HER2-positive patients. The mechanisms of action ...

Other crucial factors were the use of a highly potent cytotoxic agent (DM1) with a validated mechanism of action, the favorable exposure characteristics conferred by the MCC linker, and the potential ...

"Dual targeting of HER2-positive tumours with trastuzumab and lapatinib is undertaken because of primary and acquired resistance to both agents, their partly non-overlapping mechanisms of action ...